Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
---|
CEO | Dr. Yu-Hsin Lin M.B.A., Ph.D. |
IPO Date | April 29, 2022 |
Location | United States |
Headquarters | 5820 Oberlin Drive |
Employees | 20 |
Sector | Health Care |
Industries |
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Past 5 years
USD 1.78
USD 5.56
USD 14.84
USD 1.95
USD 3.00
USD 12.49
USD 3.29
USD 1.80
USD 4.77
USD 9.12
USD 10.53
USD 1.22
USD 2.47
USD 5.56
USD 1.60
USD 30.05
USD 1.35
USD 14.91
USD 1.51
StockViz Staff
January 15, 2025
Any question? Send us an email